Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer

Treatment of recurrent oligometastatic prostate cancer may be enhanced by the addition of Hydroxychloroquine to the current treatment regimens. Potential benefits of Hydroxychloroquine include delayed disease progression and delayed initiation of androgen deprivation therapy (ADT), thus lessening morbidity, distressing side effects, and improving functioning and quality of life in men with recurrent prostate cancer. Building on prior research at Markey, patients recently diagnosed with recurrent oligometastatic prostate cancer will be approached about participating in this study. Per standard of care, these patients undergo either surgery or radiation, in addition participants of this clinical trial will also receive Hydroxychloroquine (400 mg per day, oral medication) for 3 months. It is expected that a participant will exhibit a 50% increase of tumor suppressor PAR-4, as well as few, if any, negative side effects from Hydroxychloroquine.

Sex

Male

Minimum age

18 Years

Inclusion Criteria:

* Histologically confirmed prostate cancer that has recurred
* Three or fewer synchronous metastatic lesions (on imaging) with no evidence of residual local disease
* ECOG performance status 0 - 2
* Approval by screening eye exam (disqualifying baseline conditions listed below)
* Ability to provide informed consent

Exclusion Criteria:

* Receipt of hydroxychloroquine (HCQ) within the past 6 months
* History of allergic reactions attributed to compounds of similar chemical or biologic composition to HCQ
* Use of contraindicated medications,
* Macular degeneration
* Cataracts
* Severe baseline visual impairment, retinopathy or visual field changes
* Presence of only one functional eye
* Prior treatment with ADT including:
* Previous history of radiation or surgery to a metastatic site
* Serum testosterone less than 50 ng/ml
* History of orchiectomy
* History of pathologic fracture or spinal cord compression
* Brain or CNS metastases
* History of G-6-PD (glucose-6-phosphate dehydrogenase) deficiency
* Uncontrolled intercurrent illness
* Psychiatric illness and/or social situations that would limit compliance with study requirements.
* Patients taking other investigational agents

• BACKGROUNDTosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017 Jan;14(1):15-25. doi: 10.1038/nrurol.2016.175. Epub 2016 Oct 11. PMID 27725639
• BACKGROUNDTaylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009 Jun 1;115(11):2388-99. doi: 10.1002/cncr.24283. PMID 19399748
• BACKGROUNDBurikhanov R, Shrestha-Bhattarai T, Hebbar N, Qiu S, Zhao Y, Zambetti GP, Rangnekar VM. Paracrine apoptotic effect of p53 mediated by tumor suppressor Par-4. Cell Rep. 2014 Jan 30;6(2):271-7. doi: 10.1016/j.celrep.2013.12.020. Epub 2014 Jan 9. PMID 24412360
• BACKGROUNDHebbar N, Wang C, Rangnekar VM. Mechanisms of apoptosis by the tumor suppressor Par-4. J Cell Physiol. 2012 Dec;227(12):3715-21. doi: 10.1002/jcp.24098. PMID 22552839
• BACKGROUNDKimura T, Takabatake Y, Takahashi A, Isaka Y. Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res. 2013 Jan 1;73(1):3-7. doi: 10.1158/0008-5472.CAN-12-2464. PMID 23288916
• BACKGROUNDRatikan JA, Sayre JW, Schaue D. Chloroquine engages the immune system to eradicate irradiated breast tumors in mice. Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):761-8. doi: 10.1016/j.ijrobp.2013.07.024. PMID 24138918
• BACKGROUNDBurikhanov R, Hebbar N, Noothi SK, Shukla N, Sledziona J, Araujo N, Kudrimoti M, Wang QJ, Watt DS, Welch DR, Maranchie J, Harada A, Rangnekar VM. Chloroquine-Inducible Par-4 Secretion Is Essential for Tumor Cell Apoptosis and Inhibition of Metastasis. Cell Rep. 2017 Jan 10;18(2):508-519. doi: 10.1016/j.celrep.2016.12.051. PMID 28076793